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The role of the DNA double-strand-break (DSB) checkpoint/repair genes, ATM, BRCA1 and TP53, in sporadic breast cancer requires
clarification, since ATM and BRCA1 mutations are rare in sporadic tumours. In an attempt to explain this phenomenon, we postulated
that (i) in addition to genetic deletion, abnormal expression of DSB checkpoint/repair proteins might abolish the function of these
genes and (ii) there might be a combined effect of individual defective genes during breast cancer pathogenesis. Using a largely
homogenous group of 74 specimens of early-onset (p35 years of age) infiltrating ductal carcinomas, we examined associations
between pathological grade and genetic deletion and/or abnormal protein expression of ATM, BRCA1 and TP53. The results showed
that high-grade tumours displayed a high frequency of loss of heterozygosity (LOH) at, and/or abnormal expression of, ATM, BRCA1
and TP53. Multigenetic analysis showed abnormalities in BRCA1 to be independently associated with high-grade tumours. ATM and
TP53 appeared to play an assistant role, abnormalities in these genes significantly increasing the possibility of poor differentiation in
tumours with abnormalities in BRCA1. Furthermore, a higher number of abnormalities (LOH or abnormal expression) in these three
genes correlated with poor tumour differentiation. Thus, this study suggests that combined changes in several DSB checkpoint/repair
genes belonging to a common functional pathway are associated with breast cancer pathogenesis.
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Tumorigenesis results from a series of genomic alterations that
leads to progressive disorder of the normal mechanisms control-
ling cell growth, death and differentiation (Bishop, 1991). Our
recent studies have demonstrated that the extent of DNA double-
strand-break (DSB)-initiated genomic deletion in tumours is
significantly increased in high-grade breast tumours (Shen et al,
2000). On the basis of these findings, we hypothesised that ATM,
BRCA1 and TP53, the critical genes in the DSB checkpoint/repair
pathway, might play an important role during breast tumorigen-
esis, and that defects in these genes could result in poor tumour
differentiation. A causal link between breast cancer development
and mutation of ATM, BRCA1 and TP53 has been found in familial
breast cancer syndromes (Buchholz et al, 1999). However, the
probability of finding ATM and BRCA1 mutations in sporadic
breast cancer is low (Vorechovsky et al, 1996; Bay et al, 1998; Papa
et al, 1998). In contrast, genomic deletions at the loci harbouring
these three genes are relatively frequent (Lo et al, 1998; Rio et al,
1998; Shen et al, 2000). Genomic deletion represents one of the
‘two hits’ needed to inactivate tumour suppressor genes for cancer
formation (Knudson, 1971). Recent studies have suggested that
epigenetic mechanisms, manifested as abnormal protein expres-
sion, serve as the other hit, and are involved in abrogating the
function of certain tumour suppressor genes (Jones and Baylin,
2002). In addition, as our understanding of cancer development
extends beyond single-gene disorders to multigenetic disorders
and aetiological pathway-wide abnormalities, it is tempting to
speculate that the combined effect of several defective genes in a
common antitumour pathway could lead to more poorly
differentiated tumours. We therefore carried out the present
study, using a highly homogenous study population and a
multigenetic design, to examine the relationship between abnorm-
alities (both genetic deletion and abnormal expression) in the most
critical DSB checkpoint (ATM and TP53) and repair (BRCA1)
genes and tumour grade.
MATERIALS AND METHODS
Patients and specimens
The study subjects, 74 Chinese women with early-onset (p35 years
of age) breast cancer, were a subset of patients selected from our
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songoing hospital-based breast cancer cohort (Yang et al, 1997;
Shen et al, 2000). Breast cancer in Taiwanese (Chinese) women is
characterised by a low incidence (Yang et al, 1997), early tumour
onset (Lo et al, 1998) and novel genomic alterations (Lou et al,
1997; Shen et al, 2000). Owing to the low incidence of breast
cancer, which suggests an overall lower effect of common risk
factors, and its homogenous genetic background, the Taiwanese
population has certain advantages for studying the effects of
genetic variations. In order to obtain an aetiologically homogenous
group of study subjects, which should help in elucidating the
causes of tumour, we restricted our study to histologically
confirmed, primary infiltrating ductal carcinomas (IDCs). Direct
sequencing showed that none of the patients had germline
mutation of the BRCA1 gene. Furthermore, no patient had a
family history of breast cancer or of Li–Fraumeni syndrome
(hereditary, and associated with mutant TP53) in their first-degree
relatives, and no case of germline mutations in the ATM gene has
ever been identified in breast cancer families in Taiwan, so these
tumours were most likely sporadic. On grading using the Scarff–
Bloom–Richardson system (Le Doussal et al, 1989), the number of
IDCs of each grade was found to be similar. Institutional review
board-approved informed consent was obtained from each patient
prior to tissue collection. None of the patients had received
neoadjuvant treatment or preoperative chemotherapy or radio-
therapy, which could have caused up- or downregulation of gene
expression. Paraffin-embedded tumour tissue and peripheral
blood were obtained from each patient. To ensure that the tumour
tissue samples assayed consisted of more than 90% tumour cells,
laser capture microdissection using a PixCell laser capture
microscope (Arcturus Engineering, Mountain View, CA, USA)
was routinely performed on slides to collect the scattered tumour
cells without normal cells. Somatic DNA was extracted from
tumour tissue and genomic DNA from peripheral blood (normal
control) using a conventional proteinase K-phenol/chloroform
protocol (Shen et al, 2000). All specimens were stored at  801C
until analysed.
Allelotyping PCR and definition of loss of heterozygosity
(LOH)
A PCR-based method was used to detect loss of heterozygosity
(LOH) at loci within, or close to, ATM, BRCA1 or TP53. The allelic
status of these genes was determined using six microsatellite
markers, two for each gene: D11S1816 (11q22–11q23, close to
ATM), D11S2179 (intron 34 of ATM), D17S1322 (intron 19 of
BRCA1), D17S1323 (intron 12 of BRCA1), TP53 (intron 1 of TP53)
and D17S786 (17p13, close to TP53). The sequences of the primers
were: D11S1816, forward 50-ATTGTGAAGCTAGGTGCTGGTG- 30
and reverse 50-AAAGAGATAAAACAGATTCTGGATG-30;
D11S2179, forward 50-TAGGCAATACAGCAAGACCCTG-30 and
reverse 50-GCACTGGAATACGATTCTAGCAC-30; D17S1322, for-
ward 50-CTAGCCTGGGCAACAAACGA-30 and reverse 50-GCAGG-
AAGCAGGAATGGAAC-30; D17S1323, forward 50-TAGGAGATG-
GATTATTGGTG-30 and reverse 50-AAGCAACTTTGCAATGAGTG-
30; TP53, forward 50-CTTGTAGTCCTAGCTACTCAGCA-30 and
reverse 50-CAAAACATCCCCTACCAAAC-30; and D17S786, for-
ward 50-TACAGGGATAGGTAGCCGAG-30 and reverse 50-
GGATTTGGGCTCTTTTGTAA-30. The PCR amplification was
carried out using 100ng of DNA from tumour tissue or peripheral
blood, 0.4U of Taq polymerase, 0.2mM deoxynucleotides and
2.5mM MgCl2 in a total reaction volume of 10ml. The PCR
conditions were 951C for 12min to activate Taq polymerase,
followed by 40 cycles of denaturation (951C, 45s), annealing (551C,
30s) and extension (721C, 45s), the final elongation being
performed at 721C for 10min. PCRs were run in a GeneAmp
PCR 9600 thermocycler (PE Biosystems, Foster City, CA, USA).
PCR amplifications omitting template DNA were included in each
experiment as a control for contaminating DNA, and a house-
keeping gene (b-actin) was used as an endogenous control. PCR
products were electrophoresed on a 377 ABI PRISM sequencer,
and the fluorescent signals from the different-sized alleles recorded
and analysed using GENOTYPER (version 2.1) and GENESCAN
(version 3.1). For an informative marker (heterozygous for the two
alleles in blood specimens), the locus was considered to display
LOH when there was a four-fold or greater difference in the
relative allele intensity ratio between the tumour DNA and normal
DNA (Figure 1). Deletion of one allele of ATM, BRCA1 or TP53 was
defined by either of the two markers showing LOH.
Immunohistochemistry
Tissue specimens were fixed in 4% neutral-buffered formaldehyde,
embedded in paraffin and cut into 4mm thick sections, which were
deparaffinised for 3 5min in xylene, rehydrated in graded
alcohol and rinsed in Tris-buffered saline containing 0.1% Tween
20 (TBST). To improve antigen retrieval, dewaxed sections were
immersed in 0.001 M EDTA, pH 8.0, heated for 30min in a pressure
cooker (TAC-10KS, Tatung, Taiwan), cooled to room temperature
for 15min, then rinsed briefly in TBST. Endogenous peroxidase
was blocked by incubation for 5min at room temperature in 3.5%
hydrogen peroxide in TBST, followed by a TBST wash for 5min.
Nonspecific binding of antibodies was blocked by incubation of
the sections for 30min at room temperature with normal rabbit
serum (1:5 in TBST). After washes with TBST, primary mouse
monoclonal antibodies were added and the section incubated in a
moist chamber for 1h at room temperature. Following several
Figure 1 Allelotyping PCR to detect LOH of BRCA1 (trinucleotide marker D17S1322) in three representative breast tumours. The locus of the marker
was considered to show LOH when a four-fold or greater difference was seen in the relative allele intensity ratio (allele 1:allele 2) between the tumour and
normal DNA. Tumour (A) showed LOH at this locus. Tumour (B) showed a relative allele intensity ratio for tumour and normal DNA of 1.12, and was
considered not to show LOH at this marker. Tumour (C) was homozygous at this marker and was noninformative.
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srinses, biotinylated secondary antibody was applied for 30min at
room temperature, then the sections were rinsed and peroxidase-
linked streptavidin (Dako, Copenhagen, Denmark) was added for
20min. The chromogen was developed with AEC (Dako, Copenha-
gen, Denmark) and the slides were lightly counterstained with
haematoxylin to provide cellular detail. The primary monoclonal
antibodies used were specific for ATM (undiluted, ATX 08,
NeoMarks, CA, USA), BRCA1 (1:125 dilution, SG11, Zymed, CA,
USA) or TP53 (1:50 dilution, DO-7, DAKO, Copenhagen,
Denmark). In negative controls, the primary antibody was replaced
with TBST. In addition, the staining of infiltrating lymphocytes,
stromal cells or adjacent normal epithelial cells within the tumours
served as a normal control. Three pathologists independently
evaluated the results semiquantitatively, and any discrepancy was
resolved by joint review. Using previously reported criteria
(Yoshikawa et al, 1999; Ange `le et al, 2000), we compared the
tumours to the adjacent normal epithelium (in which most cells
show positive staining for ATM and BRCA1) and classified those
tumours with more than 25% of ATM- or BRCA1-negative tumour
cells as showing reduced expression of these proteins, all others
being classed as showing normal expression. Since mutant TP53
proteins generally have a longer half-life than wild-type TP53
protein, which leads to their nuclear accumulation (Finlay et al,
1988), tumours with more than 20% of nuclear TP53-positive
tumour cells were classed as showing aberrant expression, all
others being classed as showing normal expression. For simplicity,
both the above cases (‘reduced’ expression of ATM and BRCA1
and ‘aberrant’ expression of TP53) are referred to as ‘abnormal’
expression in the main text.
Data analysis
The Mantel-extension w
2 test was used to examine the association
between tumour grade and individual defective genes. Further-
more, to simultaneously examine all possible interactions between,
and joint effects of, ATM, BRCA1 and TP53, multigenetic analysis
based on logistic regression was performed. All statistical analyses
were performed using SAS version 8.0 software (SAS Institute Inc.,
USA).
RESULTS
Genetic deletion and tumour grade
Using four intragenetic markers (D11S2179 for ATM, D17S1322
and D17S1323 for BRCA1 and TP53 for TP53) and two adjacent
markers (D11S1816 for ATM and D17S786 for TP53), our results
showed that, after excluding noninformative tumours (six out of 74
at ATM, nine out of 74 at BRCA1 and 10/74 at TP53), the overall
frequencies of LOH were 36. 8% for ATM, 44.6% for BRCA1 and
53.1% for TP53 in these early-onset breast tumours. These
frequencies are similar to those reported previously (Shen et al,
2000). As shown in Figure 2, even in grade I tumours, the LOH
frequencies were 27.8% for ATM, 21.1% for BRCA1 and 30.0% for
TP53. When an association between the frequency of LOH at
individual genes and tumour grade (tumour differentiation) was
examined using the Mantel-extension w
2 test for trends, BRCA1
and TP53 showed a trend to a significant increase in LOH
frequency in more poorly differentiated tumours (P¼0.003,
P¼0.009, respectively).
Abnormal protein expression and tumour grade
Immunohistochemical staining showed that the frequency of
abnormal expression was 24.3% for ATM, 32.1% for BRCA1 and
28.4% for TP53, and that high-grade tumours tend to have an
increased frequency of abnormal expression of these three proteins
(Figure 3). When the frequency of abnormal expression of
individual proteins was correlated with tumour grade using the
Mantel-extension w
2 test for trends, there was a significant trend to
an increase in abnormal BRCA1 expression with higher grade
(P¼0.036) (Figure 3).
Coexistence of LOH and abnormal expression in the same
gene
We then examined whether a combination of LOH and abnormal
protein expression in the same gene was associated with poor
differentiation. The results showed that, for ATM, combined LOH
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Figure 2 Frequency of LOH at the ATM, BRCA1 or TP53 locus in early-
onset (p35 years of age) infiltrating ductal carcinoma of the breast
stratified by pathological grade. The P-values of increasing trend were
estimated using the Mantel-extension w
2 test (N¼56).
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Figure 3 Frequency of abnormal expression of ATM, BRCA1 and TP53
in early-onset (p35 years of age) infiltrating ductal carcinoma of the breast
stratified by pathological grade. The P-values were estimated using the
Mantel-extension w
2 test (N¼74).
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sand abnormal expression was not associated with tumour grade
(Table 1). However, although the number of cases showing both
LOH and abnormal expression in the same gene in each
pathological grade was small, for BRCA1 and, to a lesser extent,
TP53, these combined abnormalities were frequently seen in
association with a high tumour grade (P¼0.0003, P¼0.016,
respectively). These results are consistent with the idea that several
important DSB checkpoint/repair genes could be inactivated by
different mechanisms, and that tumours with LOH and/or
abnormal expression in the same gene are more likely to exhibit
poorer differentiation.
Defective BRCA1 is the most significant indicator, but
defective ATM or TP53 provide an additional effect
The demonstration of a significant association between tumour
grade and abnormality, either LOH or abnormal expression, at
each DSB checkpoint/repair gene prompted us to ask which gene
played the most critical role. Logistic regression analysis was
performed to resolve this issue statistically. Since the age at the
time of tumour onset is an important determinant for tumour
grade (Jones and Laird, 1999; Bogdani et al, 2002), we included the
patients’ ages in this multivariate model. The analysis showed that
LOH at BRCA1 (P¼0.02) and abnormal expression of BRCA1
protein (P¼0.03) were the only two factors significantly
and independently associated with poor pathological grade
(Table 2). This identification of the unique importance of BRCA1,
however, did not exclude a joint effect of BRCA1 and other
functionally related genes, and we therefore examined whether
abnormalities in ATM or TP53 conferred an additional risk in
cases in which BRCA1 was abnormal. The result of logistic
regression showed a more significant association with high grade
in tumours with abnormalities in BRCA1 and ATM and/or TP53
(P¼0.001) than in tumours with BRCA1 abnormalities alone
(P¼0.09) (Table 3).
Multiple defective genes are seen in high-grade tumours
Support for our hypothesis that abnormalities in individual genes
in the DSB checkpoint/repair pathway might act in combination
came from the observation of a significant association between
poor tumour differentiation and an increased number of these
genes showing LOH. As shown in Table 4, 62% of grade I tumours
showed no evidence of LOH at ATM, BRCA1 or TP53, whereas all
three genes were intact in only 5% of grade III tumours (P¼0.002).
Furthermore, the results of the Mantel-extension w
2 test for trends
confirmed the finding that an increased number of genes showing
abnormal expression correlated with poor tumour differentiation
(P¼0.026). However, since breast cancer always displays a high
degree of intratumour heterogeneity in each individual tumour, it
was possible that our finding of abnormal protein expression
based on the overall abnormal frequency described above might
fail to take into account intratumoral differences in protein
expression. To exclude this possibility, we used serial sections to
analyse the same region for the expression and subcellular location
of the proteins of interest. Two typical examples are shown in
Figure 4, in which a low-grade tumour displayed strong nuclear
staining for ATM and BRCA1 and no TP53 accumulation, while a
Table 1 Genetic deletion (detected as loss of heterozygosity (LOH)) and abnormal expression (detected by immunohistochemical staining) of the DNA
double-strand-break checkpoint/repair genes, ATM, BRCA1 and TP53, as a function of pathological grade in breast cancer
Pathological grade
Inactivating effects No. of informative tumours I II III P-value
a for trend
ATM 68 NS
No LOH plus normal expression 33 13 (72.2%) 12 (48.0%) 8 (32.0%)
Either LOH or reduced expression 30 3 (16.7%) 11 (44.0%) 16 (64.0%)
LOH plus reduced expression 5 2 (11.1%) 2 (8.0%) 1 (4.0%)
BRCA1 65 0.0003
No LOH plus normal expression 22 12 (63.2%) 7 (31.8%) 3 (12.5%)
Either LOH or reduced expression 33 6 (31.6%) 13 (59.1%) 14 (58.3%)
LOH plus reduced expression 10 1 (5.2%) 2 (9.1%) 7 (29.2%)
TP53 64 0.0161
No LOH plus normal expression 23 11 (55.0%) 7 (30.4%) 5 (23.8%)
Either LOH or aberrant expression 29 7 (35.0%) 13 (56.5%) 9 (42.9%)
LOH plus aberrant expression 12 2 (10.0%) 3 (13.1%) 7 (33.3%)
aP-values estimated using the Mantel-extension w
2chi-squared test.
Table 2 Logistic regression and odds ratio showing the relationship
between pathological grade and either LOH or abnormal expression of
ATM, BRCA1 or TP53
Variable
b regression
coefficient OR (95% CI)
a P-value
LOH at ATM  0.08 0.93 (0.29–2.96) NS
LOH at BRCA1 1.48 4.38 (1.25–15.41) 0.02
LOH at TP53 0.61 1.84 (0.59–5.71) NS
Reduced ATM expression  0.13 0.88 (0.19–4.04) NS
Reduced BRCA1 expression 1.35 3.84 (1.13–13.05) 0.03
Aberrant TP53 accumulation 0.55 1.74 (0.46–6.57) NS
aThe odds ratio was adjusted for age (p30 years vs 430 years).
Table 3 Logistic regression analysis of breast tumour pathological grade
as a function of abnormalities in BRCA1 alone or abnormalities in BRCA1
plus abnormalities in ATM and/or TP53
Genetic deletion and/or
protein abnormalities
b regression
coefficient P-value
a,b
BRCA1 alone
c 2.43 0.090
BRCA1 combined with ATM and/or TP53
d 3.90 0.001
aThe test was adjusted for age (p30 years vs 430 years).
bThe reference group was
defined as tumours with no LOH at, and no abnormal expression of, all three genes
(ATM, BRCA1 and TP53).
cAbnormalities in BRCA1 (LOH and/or abnormal
expression) alone.
dAbnormalities in BRCA1 combined with abnormalities in ATM
and/or TP53 (either LOH or aberrant expression).
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proteins.
DISCUSSION
The rationale for a mutator contributing to the genomic instability
that leads to cancer progression is that, instead of being a single-
gene disease, cancer is caused by aberrations arising from a
complex interconnecting network of multiple regulatory genes
involved in normal growth control processes and the maintenance
of genomic stability (Orr-Weaver and Weinberg, 1998; Loeb and
Loeb, 2000). This rationale supports our approach of simulta-
neously examining the role of three important genes (ATM, BRCA1
and TP53) involved in the DSB checkpoint/repair pathway.
Although abnormalities of individual DSB checkpoint/repair genes
or proteins have been reported (Waha et al, 1998; Wilson et al,
1999; Ange `le et al, 2000), almost all of these have been studied in
isolation without considering the common pathway involved. In
contrast, in the present study, using a largely homogeneous group
of 74 early-onset IDCs and a multigenetic model, we have
evaluated the tumorigenic contribution of LOH and/or abnormal
expression of these genes. In terms of methodology, we selected
intragenic markers and used laser capture microdissection for our
LOH analysis to provide an unbiased estimate of the genetic status
of these genes in cancer cells, and our careful examination of
protein expression based on serial sections excluded the possibility
of an effect of intratumour heterogeneity. The results (Figure 2)
showed that loci harbouring ATM, BRCA1 or TP53 displayed a
high frequency of LOH in low-grade tumours, suggesting that
genetic deletion of these DSB checkpoint/repair genes frequently
occurs during the early stage of breast tumour. This is consistent
with the results of our previous study (Shen et al, 2000), which
suggested that breast cancer progression is driven by DSB-initiated
chromosomal instability. In addition, our immunohistochemical
study (Figure 3) showed that high-grade tumours tended to have
an increased frequency of abnormal expression of these three
proteins and, in particular, that abnormal BRCA1 expression was
related to poor differentiation (Figure 3), supporting an important
contribution of DSB checkpoint/repair genes to breast cancer
pathogenesis.
The present study also examined whether combined LOH and
abnormal expression occurring at the same gene could contribute
to the pathogenesis of breast cancer, and our findings for TP53 and
BRCA1 seem to be in line with this hypothesis (Table 1). However,
different mechanisms are involved in the effects of combined LOH
and abnormal expression of TP53 and BRCA1. In sporadic cancers,
LOH at the TP53 locus is usually accompanied by somatic
mutation at TP53 (Yang et al, 1997; Kurose et al, 2002), leading
to abnormal accumulation of this protein. Thus, a high frequency
of poorly differentiated tumours showing both LOH at, and
aberrant expression of, TP53 can be explained mechanistically. In
contrast, BRCA1 mutations are rare in sporadic breast cancer,
suggesting that BRCA1 is inactivated by nonmutational mechan-
isms (Papa et al, 1998), since epigenetic mechanisms (e.g.
promoter hypermethylation), manifested as abnormal expression,
have been shown to be involved in abrogating the function of
certain tumour suppressor genes (such as BRCA1), which are
already targeted by LOH (Dobrovic and Simpfendorfer, 1997; Jones
and Baylin, 2002). Our finding that combined LOH and abnormal
expression in BRCA1 was associated with a higher tumour grade
therefore re-emphasises the importance of the different mechan-
isms that may affect expression, and this finding is of particular
tumorigenic importance in sporadic cancer, as the frequency of
somatic mutation in many tumour suppressor genes involved in
regulating genomic stability is extremely low. In the present study,
we also found that LOH was more frequent than abnormal protein
expression at ATM, BRCA1 and TP53. One possible explanation for
this is that expression of the remaining allele might increase to
compensate for the loss of expression due to the deleted allele
(Liao et al, 2003).
The observation that the only gene of the three tested found by
multigenetic logistic regression analysis to be independently
associated with tumour differentiation was BRCA1 (Table 2) is
consistent with the tumour spectrum observed in familial cancer
syndromes caused by mutation of ATM, BRCA1 or TP53, with only
BRCA1 being specifically associated with familial breast cancer
(Holt et al, 1996). However, the present study showed that a joint
effect of abnormalities, either LOH or abnormal expression, in
BRCA1, ATM and TP53 is also an important factor associated with
poor differentiation (Tables 3 and 4). This effect can be explained
by known mechanisms involving interactions between BRCA1,
ATM and TP53 (Xu et al, 1999; Gatei et al, 2000; Wang, 2000;
Khanna and Jackson, 2001), including (i) ATM serves as the
upstream sensor and, upon DSB formation, phosphorylates BRCA1
and TP53 to trigger DSB repair and cell cycle regulation and (ii) for
breast cancer formation, breast epithelium cells that are genomi-
cally unstable because of defective BRCA1-associated repair also
Table 4 Pathological grade as a function of the number of defective double-strand-break (DSB) checkpoint/repair genes harboured by individual tumours,
detected as either loss of heterozygocity (LOH) or abnormal expression
Pathological grade
I II III
No. (%) No. (%) No. (%) P-value
a
No. of genes (ATM, BRCA1 or TP53) with LOH (N¼56)
b 0.002
None 10 (62.5%) 4 (20.0%) 1 (5.0%)
One gene 2 (12.5%) 5 (25.0%) 7 (35.0%)
Two or three genes 4 (25.0%) 11 (55.0%) 12 (60.0%)
No. of proteins (ATM, BRCA1 or TP53) showing abnormal expression (N¼74) 0.026
None 12 (40.0%) 12 (40.0%) 6 (20.0%)
One protein 5 (21.7%) 7 (30.4%) 11 (47.8%)
Two or three proteins 4 (19.1%) 7 (33.3%) 10 (47.6%)
aMantel-extension test for trend comparing the frequency distribution of pathological grades in tumours showing LOH at (abnormal expression of) one or two/three DSB
checkpoint/repair genes (ATM, BRCA1 and TP53) and in tumours with no LOH at (no abnormal expression of) any of these three genes.
bThe 56 tumours were informative
(heterozygous for the two alleles of either of the two microsatellite markers reflecting the genetic status of the individual genes) at ATM, BRCA1 and TP53.
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order to escape checkpoint surveillance. More importantly, our
demonstration that defective DSB checkpoint/repair genes in a
common functional pathway may act together, leading to poor
differentiation of breast cancer, is consistent with recent evidence
suggesting the joint contribution of different genes in disease
aetiology and cancer development. The combination of hetero-
zygous abnormalities in different, but functionally related, genes is
known to play a causal role in the pathogenesis of certain genetic
syndromes (Cressman et al, 1999; Balmain, 2002). Furthermore,
support for a joint carcinogenic effect comes from previous
observational studies. For instance, there is a trend towards an
increased risk of breast cancer in women harbouring a greater
number of putative high-risk genotypes of oestrogen-metabolising
genes or nonhomologous end-joining genes (Huang et al, 1999; Fu
et al, 2003). Our findings provide additional support for the
possibility of a joint effect of defects in different genes and
emphasise the need to examine the whole tumorigenic pathway to
obtain a better insight into the molecular changes involved in
cancer development and progression.
ACKNOWLEDGEMENTS
We thank Professor Bruce AJ Ponder of the Hutchison/MRC
Research Centre of the University of Cambridge and Professors
Chien-Jen Chen and Su-Ming Hsu of the National Taiwan
University for their critical reviewing of the manuscript.
AB
C D
E F
G H
Figure 4 Expression of DNA DSB checkpoint/repair proteins in infiltrating ductal carcinoma of the breast. Adjacent serial sections from a grade I tumour
(differentiation score of 5 points) (A, C, E, G) or a grade III tumour (differentiation score of 8 points) (B, D, F, H) were stained with haematoxylin–eosin
(G, H) or with antibodies against ATM (A, B), BRCA1 (C, D) or TP53 (E, F). Original magnification  200.
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